Agilent CEO on 3Q Earnings, Life Sciences Outlook
THE SO WHAT
7% organic growth and solid EPS in life sciences is a reminder: picks-and-shovels for regulated R&D cycles are less correlated with software sentiment. If you sell into labs or biopharma, anchor your planning to capex and pipeline data, not the Nasdaq.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechRussia's bid to launch a Starlink rival is falling embarrassingly short — 'Rassvet' is losing satellites faster than it can build them
Rassvet’s deployment struggles underline how hard it is to replicate Starlink’s vertically integrated machine—launch cadence, manufacturing, and ground infra all have to work. If your product assumes global, low-latency broadband, plan for asymmetric coverage and reliability by provider and region well into the late 2020s.
Deep & Emerging TechEverpure CEO on Earnings, AI Hyperscaler Impact
A 38% revenue jump to roughly $600M with 50% core product growth shows how AI hyperscaler buildouts are spilling into adjacent hardware and infra vendors. If you’re in that supply chain, lock in multi-year volume commitments now—this wave is rewarding whoever can guarantee delivery, not just price.
Deep & Emerging TechMarvell is boosting its forecasts, but that’s not enough to lift its stock
Marvell’s raised outlook but flat stock is another data point that AI-adjacent semis are now priced for perfection. If you’re a buyer, expect more disciplined capacity and pricing from suppliers who know Wall Street won’t reward growth without clear AI leverage.
Deep & Emerging TechUS military bought commercial satellite images of alleged narco airstrips, Chinese naval fleet
The US military leaning on commercial satellite imagery for narco airstrips and foreign naval tracking shows how dual-use space data has become operational, not experimental. If you operate in EO or analytics, assume your customer base now includes defense and law enforcement—with all the compliance, export control, and reputational questions that follow.